

**BEFORE THE
BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

In the Matter of the Second Amended Accusation
Against:

**CALIFORNIA PHARMACY AND
COMPOUNDING CENTER**

4000 Birch Street, Suite 120
Newport Beach, CA 92660

**Pharmacy Permit No. PHY 49828
Sterile Compounding License No. LSC
99542**

and

DAVID JOSEPH SCHAPIRO

14501 Larch Avenue
Irvine, CA 92606

Pharmacist License No. RPH 26704

Case No. 4628

OAH No. 2014060941

**STIPULATED SETTLEMENT AND
DISCIPLINARY ORDER [AS TO DAVID
JOSEPH SCHAPIRO ONLY]**

Respondents.

DECISION AND ORDER

The attached Stipulated Settlement and Disciplinary Order is hereby adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This Decision shall become effective at 5:00 p.m. on September 9, 2016.

It is so ORDERED on August 10, 2016.

BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA



By

Amy Gutierrez, Pharm.D.
Board President

1 KAMALA D. HARRIS
Attorney General of California
2 ANTOINETTE CINCOTTA
Supervising Deputy Attorney General
3 MARICHELE S. TAHIMIC
Deputy Attorney General
4 State Bar No. 147392
600 West Broadway, Suite 1800
5 San Diego, CA 92101
P.O. Box 85266
6 San Diego, CA 92186-5266
Telephone: (619) 645-3154
7 Facsimile: (619) 645-2061
Attorneys for Complainant

8
9 **BEFORE THE**
BOARD OF PHARMACY
10 **DEPARTMENT OF CONSUMER AFFAIRS**
STATE OF CALIFORNIA

11 In the Matter of the Second Amended
12 Accusation Against:

Case No. 4628

OAH No. 2014060941

13 **CALIFORNIA PHARMACY AND**
14 **COMPOUNDING CENTER**
4000 Birch Street, Suite 120
15 Newport Beach, CA 92660

STIPULATED SETTLEMENT AND
DISCIPLINARY ORDER AS TO DAVID
JOSEPH SCHAPIRO ONLY

16 **Pharmacy Permit No. PHY 49828**
17 **Sterile Compounding License No. LSC**
99542

18 and

19 **DAVID JOSEPH SCHAPIRO**
14501 Larch Avenue
20 Irvine, CA 92606

21 **Pharmacist License No. RPH 26704**

22 Respondents.
23

24 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-
25 entitled proceedings that the following matters are true:

26 PARTIES

27 1. Virginia Herold (Complainant) is the Executive Officer of the Board of Pharmacy.
28 She brought this action solely in her official capacity and is represented in this matter by Kamala

1 D. Harris, Attorney General of the State of California, by Marichelle S. Tahimic, Deputy
2 Attorney General.

3 2. Respondent David Joseph Schapiro ("Respondent") is represented in this proceeding
4 by attorney Ivan Petrzeka, whose address is: 2855 Michelle Drive, Suite 180, Irvine, CA 92606-
5 1027, telephone ((530) 366-8485.

6 3. On or about July 16, 1970, the Board of Pharmacy issued Pharmacist License No.
7 RPH 26704 to David Joseph Schapiro. The Pharmacist License was in full force and effect at all
8 times relevant to the charges brought in Second Amended Accusation No. 4628, and will expire
9 on July 31, 2017, unless renewed.

10 JURISDICTION

11 4. Second Amended Accusation No. 4628 was filed before the Board of Pharmacy
12 (Board), Department of Consumer Affairs, and is currently pending against Respondent. The
13 Accusation and all other statutorily required documents were properly served on Respondent on
14 May 27, 2014. Respondent timely filed its Notice of Defense contesting the Accusation. Second
15 Amended Accusation No. 4628 was filed before the Board on May 2, 2016.

16 5. A copy of Second Amended Accusation No. 4628 is attached as exhibit A and
17 incorporated herein by reference.

18 ADVISEMENT AND WAIVERS

19 6. Respondent has carefully read, fully discussed with counsel, and understands the
20 charges and allegations in Second Amended Accusation No. 4628. Respondent has also carefully
21 read, fully discussed with counsel, and understands the effects of this Stipulated Settlement and
22 Disciplinary Order.

23 7. Respondent is fully aware of its legal rights in this matter, including the right to a
24 hearing on the charges and allegations in the Second Amended Accusation; the right to confront
25 and cross-examine the witnesses against them; the right to present evidence and to testify on its
26 own behalf; the right to the issuance of subpoenas to compel the attendance of witnesses and the
27 production of documents; the right to reconsideration and court review of an adverse decision;
28

1 and all other rights accorded by the California Administrative Procedure Act and other applicable
2 laws.

3 8. Respondent voluntarily, knowingly, and intelligently waives and gives up each and
4 every right set forth above.

5 CULPABILITY

6 9. Respondent understands and agrees that the charges and allegations in Second
7 Amended Accusation No. 4628, if proven at a hearing, constitute cause for imposing discipline
8 upon his Pharmacist License.

9 10. For the purpose of resolving the Second Amended Accusation without the expense
10 and uncertainty of further proceedings, Respondent agrees that, at a hearing, Complainant could
11 establish a factual basis for the charges in the Second Amended Accusation, and that Respondent
12 hereby gives up his right to contest those charges.

13 CONTINGENCY

14 11. This stipulation shall be subject to approval by the Board of Pharmacy. Respondent
15 understands and agrees that counsel for Complainant and the staff of the Board of Pharmacy may
16 communicate directly with the Board regarding this stipulation and settlement, without notice to
17 or participation by Respondent or its counsel. By signing the stipulation, Respondent understands
18 and agrees that he may not withdraw his agreement or seek to rescind the stipulation prior to the
19 time the Board considers and acts upon it. If the Board fails to adopt this stipulation as its
20 Decision and Order, the Stipulated Settlement and Disciplinary Order shall be of no force or
21 effect, except for this paragraph, it shall be inadmissible in any legal action between the parties,
22 and the Board shall not be disqualified from further action by having considered this matter.

23 12. The parties understand and agree that Portable Document Format (PDF) and facsimile
24 copies of this Stipulated Settlement and Disciplinary Order, including PDF and facsimile
25 signatures thereto, shall have the same force and effect as the originals.

26 13. This Stipulated Settlement and Disciplinary Order is intended by the parties to be an
27 integrated writing representing the complete, final, and exclusive embodiment of their agreement.
28 It supersedes any and all prior or contemporaneous agreements, understandings, discussions,

1 negotiations, and commitments (written or oral). This Stipulated Settlement and Disciplinary
2 Order may not be altered, amended, modified, supplemented, or otherwise changed except by a
3 writing executed by an authorized representative of each of the parties.

4 14. In consideration of the foregoing admissions and stipulations, the parties agree that
5 the Board may, without further notice or formal proceeding, issue and enter the following
6 Disciplinary Order:

7 **DISCIPLINARY ORDER**

8 IT IS HEREBY ORDERED that Pharmacist License No. RPH 26704 issued to Respondent
9 David Joseph Schapiro is revoked. However, the revocation is stayed and Respondent is placed
10 on probation for four (4) years on the following terms and conditions.

11 **1. Obey All Laws**

12 Respondent shall obey all state and federal laws and regulations.

13 Respondent shall report any of the following occurrences to the board, in writing, within
14 seventy-two (72) hours of such occurrence:

- 15 • an arrest or issuance of a criminal complaint for violation of any provision of the
16 Pharmacy Law, state and federal food and drug laws, or state and federal controlled
17 substances laws
- 18 • a plea of guilty or nolo contendere in any state or federal criminal proceeding to any
19 criminal complaint, information or indictment
- 20 • a conviction of any crime
- 21 • discipline, citation, or other administrative action filed by any state or federal agency
22 which involves Respondent's pharmacist license or which is related to the practice of
23 pharmacy or the manufacturing, obtaining, handling, distributing, billing, or charging
24 for any drug, device or controlled substance.

25 Failure to timely report such occurrence shall be considered a violation of probation.

26 **2. Report to the Board**

27 Respondent shall report to the board quarterly, on a schedule as directed by the board or its
28 designee. The report shall be made either in person or in writing, as directed. Among other

1 requirements, respondent shall state in each report under penalty of perjury whether there has
2 been compliance with all the terms and conditions of probation. Failure to submit timely reports
3 in a form as directed shall be considered a violation of probation. Any period(s) of delinquency
4 in submission of reports as directed may be added to the total period of probation. Moreover, if
5 the final probation report is not made as directed, probation shall be automatically extended until
6 such time as the final report is made and accepted by the board.

7 **3. Interview with the Board**

8 Upon receipt of reasonable prior notice, respondent shall appear in person for interviews
9 with the board or its designee, at such intervals and locations as are determined by the board or its
10 designee. Failure to appear for any scheduled interview without prior notification to board staff,
11 or failure to appear for two (2) or more scheduled interviews with the board or its designee during
12 the period of probation, shall be considered a violation of probation.

13 **4. Cooperate with Board Staff**

14 Respondent shall cooperate with the board's inspection program and with the board's
15 monitoring and investigation of respondent's compliance with the terms and conditions of their
16 probation. Failure to cooperate shall be considered a violation of probation.

17 **5. Continuing Education**

18 Respondent shall provide evidence of efforts to maintain skill and knowledge as a
19 pharmacist as directed by the board or its designee.

20 **6. Notice to Employers**

21 During the period of probation, respondent shall notify all present and prospective
22 employers of the decision in case number 4628 and the terms, conditions and restrictions imposed
23 on respondent by the decision, as follows:

24 Within thirty (30) days of the effective date of this decision, and within fifteen (15) days of
25 respondent undertaking any new employment, respondent shall cause their direct supervisor,
26 pharmacist-in-charge (including each new pharmacist-in-charge employed during respondent's
27 tenure of employment) and owner to report to the board in writing acknowledging that the listed
28 individual(s) has/have read the decision in case number 4628, and terms and conditions imposed

1 thereby. It shall be respondent's responsibility to ensure that their employer(s) and/or
2 supervisor(s) submit timely acknowledgment(s) to the board.

3 If respondent works for or is employed by or through a pharmacy employment service,
4 respondent must notify their direct supervisor, pharmacist-in-charge, and owner at every entity
5 licensed by the board of the terms and conditions of the decision in case number 4628 in advance
6 of the respondent commencing work at each licensed entity. A record of this notification must be
7 provided to the board upon request.

8 Furthermore, within thirty (30) days of the effective date of this decision, and within fifteen
9 (15) days of respondent undertaking any new employment by or through a pharmacy employment
10 service, respondent shall cause their direct supervisor with the pharmacy employment service to
11 report to the board in writing acknowledging that they has read the decision in case number 4628
12 and the terms and conditions imposed thereby. It shall be respondent's responsibility to ensure
13 that their employer(s) and/or supervisor(s) submit timely acknowledgment(s) to the board.

14 Failure to timely notify present or prospective employer(s) or to cause that/those
15 employer(s) to submit timely acknowledgments to the board shall be considered a violation of
16 probation.

17 "Employment" within the meaning of this provision shall include any full-time,
18 part-time, temporary, relief or pharmacy management service as a pharmacist or any
19 position for which a pharmacist license is a requirement or criterion for employment,
20 whether the respondent is an employee, independent contractor or volunteer.

21 **7. No Supervision of Interns, Serving as Pharmacist-in-Charge (PIC), Serving as**
22 **Designated Representative-in-Charge, or Serving as a Consultant**

23 During the period of probation, respondent shall not supervise any intern pharmacist, be the
24 pharmacist-in-charge or designated representative-in-charge of any entity licensed by the board
25 nor serve as a consultant unless otherwise specified in this order. Assumption of any such
26 unauthorized supervision responsibilities shall be considered a violation of probation.

27 ///

28 ///

1 **8. Reimbursement of Board Costs**

2 As a condition precedent to successful completion of probation, respondent shall pay to the
3 board its costs of investigation and prosecution in the amount of \$3,495.42. Respondent shall
4 make said payments as directed by the Board.

5 There shall be no deviation from this schedule absent prior written approval by the board or
6 its designee. Failure to pay costs by the deadline(s) as directed shall be considered a violation of
7 probation.

8 **9. Probation Monitoring Costs**

9 Respondent shall pay any costs associated with probation monitoring as determined by the
10 board each and every year of probation. Such costs shall be payable to the board on a schedule as
11 directed by the board or its designee. Failure to pay such costs by the deadline(s) as directed shall
12 be considered a violation of probation.

13 **10. Status of License**

14 Respondent shall, at all times while on probation, maintain an active, current license with
15 the board, including any period during which suspension or probation is tolled. Failure to
16 maintain an active, current license shall be considered a violation of probation.

17 If respondent's license expires or is cancelled by operation of law or otherwise at any time
18 during the period of probation, including any extensions thereof due to tolling or otherwise, upon
19 renewal or reapplication respondent's license shall be subject to all terms and conditions of this
20 probation not previously satisfied.

21 **11. License Surrender While on Probation/Suspension**

22 Following the effective date of this decision, should respondent cease practice due to
23 retirement or health, or be otherwise unable to satisfy the terms and conditions of probation,
24 respondent may tender their license to the board for surrender. The board or its designee shall
25 have the discretion whether to grant the request for surrender or take any other action it deems
26 appropriate and reasonable. Upon formal acceptance of the surrender of the license, respondent
27 will no longer be subject to the terms and conditions of probation. This surrender constitutes a
28 record of discipline and shall become a part of the respondent's license history with the board.

1 Upon acceptance of the surrender, respondent shall relinquish their pocket and wall license
2 to the board within ten (10) days of notification by the board that the surrender is accepted.
3 Respondent may not reapply for any license from the board for three (3) years from the effective
4 date of the surrender. Respondent shall meet all requirements applicable to the license sought as
5 of the date the application for that license is submitted to the board, including any outstanding
6 costs.

7 **12. Notification of a Change in Name, Residence Address, Mailing Address or**
8 **Employment**

9 Respondent shall notify the board in writing within ten (10) days of any change of
10 employment. Said notification shall include the reasons for leaving, the address of the new
11 employer, the name of the supervisor and owner, and the work schedule if known. Respondent
12 shall further notify the board in writing within ten (10) days of a change in name, residence
13 address, mailing address, or phone number.

14 Failure to timely notify the board of any change in employer(s), name(s), address(es), or
15 phone number(s) shall be considered a violation of probation.

16 **13. Tolling of Probation**

17 Except during periods of suspension, respondent shall, at all times while on probation, be
18 employed as a pharmacist in California for a minimum of 40 hours per calendar month. Any
19 month during which this minimum is not met shall toll the period of probation, i.e., the period of
20 probation shall be extended by one month for each month during which this minimum is not met.
21 During any such period of tolling of probation, respondent must nonetheless comply with all
22 terms and conditions of probation.

23 Should respondent, regardless of residency, for any reason (including vacation) cease
24 practicing as a pharmacist for a minimum of 40 hours per calendar month in California,
25 respondent must notify the board in writing within ten (10) days of the cessation of practice, and
26 must further notify the board in writing within ten (10) days of the resumption of practice. Any
27 failure to provide such notification(s) shall be considered a violation of probation.

1 It is a violation of probation for respondent's probation to remain tolled pursuant to the
2 provisions of this condition for a total period, counting consecutive and non-consecutive months,
3 exceeding thirty-six (36) months.

4 "Cessation of practice" means any calendar month during which respondent is
5 not practicing as a pharmacist for at least 40 hours, as defined by Business and
6 Professions Code section 4000 et seq. "Resumption of practice" means any calendar
7 month during which respondent is practicing as a pharmacist for at least 40 hours as a
8 pharmacist as defined by Business and Professions Code section 4000 et seq.

9 **14. Violation of Probation**

10 If a respondent has not complied with any term or condition of probation, the board shall
11 have continuing jurisdiction over respondent, and probation shall automatically be extended, until
12 all terms and conditions have been satisfied or the board has taken other action as deemed
13 appropriate to treat the failure to comply as a violation of probation, to terminate probation, and
14 to impose the penalty that was stayed.

15 If respondent violates probation in any respect, the board, after giving respondent notice
16 and an opportunity to be heard, may revoke probation and carry out the disciplinary order that
17 was stayed. Notice and opportunity to be heard are not required for those provisions stating that a
18 violation thereof may lead to automatic termination of the stay and/or revocation of the license. If
19 a petition to revoke probation or an accusation is filed against respondent during probation, the
20 board shall have continuing jurisdiction and the period of probation shall be automatically
21 extended until the petition to revoke probation or accusation is heard and decided and the charges
22 and allegations in the Second Amended Accusation shall be deemed true and correct.

23 **15. Completion of Probation**

24 Upon written notice by the board or its designee indicating successful completion of
25 probation, respondent's license will be fully restored.

26 **16. Remedial Education**

27 Within sixty (60) days of the effective date of this decision, respondent shall submit to the
28 board or its designee, for prior approval, an appropriate program of remedial education in

1 compounding and sterile compounding. The program of remedial education in compounding and
2 sterile compounding shall consist of at least ten (10) hours per year for each year of the four-year
3 probation period, which shall be completed prior to the completion of probation and at
4 respondent's own expense. All remedial education shall be in addition to, and shall not be
5 credited toward, continuing education (CE) courses used for license renewal purposes.

6 Failure to timely submit or complete the approved remedial education shall be considered a
7 violation of probation. The period of probation will be automatically extended until such
8 remedial education is successfully completed and written proof, in a form acceptable to the board,
9 is provided to the board or its designee.

10 Following the completion of each course, the board or its designee may require the
11 respondent, at their own expense, to take an approved examination to test the respondent's
12 knowledge of the course. If the respondent does not achieve a passing score on the examination,
13 this failure shall be considered a violation of probation. Any such examination failure shall
14 require respondent to take another course approved by the board in the same subject area.

15 17. Supervised Practice

16 During the period of probation, respondent shall practice only under the supervision of a
17 licensed pharmacist not on probation with the board. Upon and after the effective date of this
18 decision, respondent shall not practice pharmacy and his license shall be automatically suspended
19 until a supervisor is approved by the board or its designee. The supervision shall be, as required
20 by the board or its designee, either:

21 Continuous – At least 75% of a work week

22 Substantial - At least 50% of a work week

23 Partial - At least 25% of a work week

24 Daily Review - Supervisor's review of probationer's daily activities within 24 hours

25 Within thirty (30) days of the effective date of this decision, respondent shall have his
26 supervisor submit notification to the board in writing stating that the supervisor has read the
27 decision in Second Amended Accusation Case Number 4628 and is familiar with the required
28 level of supervision as determined by the board or its designee. It shall be the respondent's

1 responsibility to ensure that his employer(s), pharmacist-in-charge and/or supervisor(s) submit
2 timely acknowledgement(s) to the board. Failure to cause the direct supervisor and the
3 pharmacist-in-charge to submit timely acknowledgements to the board shall be considered a
4 violation of probation.

5 If respondent changes employment, it shall be the respondent's responsibility to ensure that
6 his employer(s), pharmacist-in-charge and/or supervisor(s) submit timely acknowledgement(s) to
7 the board. Respondent shall have his new supervisor, within fifteen (15) days after employment
8 commences, submit notification to the board in writing stating the direct supervisor and
9 pharmacist-in-charge have read the decision in Second Amended Accusation Case Number 4628
10 and is familiar with the level of supervision as determined by the board. Respondent shall not
11 practice pharmacy and his license shall be automatically suspended until the board or its designee
12 approves a new supervisor. Failure to cause the direct supervisor and the pharmacist-in-charge to
13 submit timely acknowledgements to the board shall be considered a violation of probation.

14 Within ten (10) days of leaving employment, respondent shall notify the board in writing.

15 During suspension, respondent shall not enter any pharmacy area or any portion of the
16 licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of
17 drugs which is licensed by the board, or any manufacturer, or where dangerous drugs and devices
18 or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act
19 involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient
20 consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the
21 board, or have access to or control the ordering, manufacturing or dispensing of dangerous drugs
22 and controlled substances. Respondent shall not resume practice until notified by the board.

23 During suspension, respondent shall not engage in any activity that requires the
24 professional judgment of a pharmacist. Respondent shall not direct or control any aspect of the
25 practice of pharmacy. Respondent shall not perform the duties of a pharmacy technician or a
26 designated representative for any entity licensed by the board.

27 ///

28 ///

1 Subject to the above restrictions, respondent may continue to own or hold an interest in any
2 licensed premises in which they holds an interest at the time this decision becomes effective
3 unless otherwise specified in this order.

4 Failure to comply with this suspension shall be considered a violation of probation.

5 **18. No Ownership of Licensed Premises**

6 Respondent shall not own, have any legal or beneficial interest in, or serve as a manager,
7 administrator, member, officer, director, trustee, associate, or partner of any business, firm,
8 partnership, or corporation currently or hereinafter licensed by the board. Respondent shall sell
9 or transfer any legal or beneficial interest in any entity licensed by the board within ninety (90)
10 days following the effective date of this decision and shall immediately thereafter provide written
11 proof thereof to the board. Failure to timely divest any legal or beneficial interest(s) or provide
12 documentation thereof shall be considered a violation of probation.

13 **19. Ethics Course**

14 Within sixty (60) calendar days of the effective date of this decision, respondent shall enroll
15 in a course in ethics, at respondent's expense, approved in advance by the board or its designee.
16 Failure to initiate the course during the first year of probation, and complete it within the second
17 year of probation, is a violation of probation. The ethics course shall be in addition to, and shall
18 not be credited toward, continuing education (CE) courses used for license renewal purposes

19 Respondent shall submit a certificate of completion to the board or its designee within five
20 days after completing the course.

21 ACCEPTANCE

22 I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully
23 discussed it with my attorney, Ivan Petrzeka. I understand the stipulation and the effect it will
24 have on my Pharmacist License. I enter into this Stipulated Settlement and Disciplinary Order

25 ///

26 ///

27 ///

28 ///


1 voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the
2 Board of Pharmacy.

3
4 DATED: 05-25-2016


5 DAVID JOSEPH SCHAPIRO
6 Respondent

7 I have read and fully discussed with Respondent David Joseph Schapiro the terms and
8 conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order.
9 I approve its form and content.

10
11 DATED: May 25, 2016


12 IVAN PETRZELKA
13 Attorney for Respondent


14 ENDORSEMENT

15 The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully
16 submitted for consideration by the Board of Pharmacy.

17
18 Dated: May 25, 2016

Respectfully submitted;

19
20 KAMALA D. HARRIS
21 Attorney General of California
22 ANTOINETTE CINCOTTA
23 Supervising Deputy Attorney General


24 MARICHELE S. TANIMIC
25 Deputy Attorney General
26 Attorneys for Complainant

27 SD2013805160
28 81352548.doc

Exhibit A

Second Amended Accusation No. 4628

1 KAMALA D. HARRIS
Attorney General of California
2 JAMES M. LEDAKIS
Supervising Deputy Attorney General
3 MARICHELLE S. TAHIMIC
Deputy Attorney General
4 State Bar No. 147392
110 West "A" Street, Suite 1100
5 San Diego, CA 92101
P.O. Box 85266
6 San Diego, CA 92186-5266
Telephone: (619) 645-3154
7 Facsimile: (619) 645-2061
Attorneys for Complainant

8
9 **BEFORE THE**
BOARD OF PHARMACY
10 **DEPARTMENT OF CONSUMER AFFAIRS**
STATE OF CALIFORNIA

11 In the Matter of the Second Amended
12 Accusation Against:

Case No. 4628

13 **CALIFORNIA PHARMACY AND**
COMPOUNDING CENTER
14 4000 Birch Street, Suite 120
15 Newport Beach, CA 92660

SECOND AMENDED
ACCUSATION

16 Pharmacy Permit No. PHY 49828
17 Sterile Compounding License No. LSC
99542

18 and

19 **DAVID JOSEPH SCHAPIRO**
14501 Larch Avenue
20 Irvine, CA 92606

21 Pharmacist License No. RPH 26704

22 Respondents.
23

24 Complainant alleges:

25 **PARTIES**

26 1. Virginia Herold (Complainant) brings this Second Amended Accusation solely in her
27 official capacity as the Executive Officer of the Board of Pharmacy, Department of Consumer
28 Affairs.

2. On or about April 1, 2009, the Board of Pharmacy issued Pharmacy Permit Number PHY 49828 to California Pharmacy and Compounding Center (Respondent). The Pharmacy Permit was in full force and effect at all times relevant to the charges brought herein and will expire on April 1, 2016, unless renewed.

3. On or about April 2, 2009, the Board of Pharmacy issued Sterile Compounding License Number LSC 99542 to California Pharmacy and Compounding Center (Respondent). The Sterile Compounding License was in full force and effect at all times relevant to the charges brought herein and will expire on April 1, 2016, unless renewed.

4. On or about July 16, 1970, the Board of Pharmacy issued Pharmacist License Number RPH 26704 to David Joseph Schapiro (Respondent). The Pharmacist License was in full force and effect at all times relevant to the charges brought herein and will expire on July 31, 2017, unless renewed. Respondent Schapiro was the Pharmacist-In-Charge ("PIC") of CPCC and has been the PIC since April 1, 2009.

JURISDICTION

5. This Second Amended Accusation is brought before the Board of Pharmacy (Board), Department of Consumer Affairs, under the authority of the following laws. All section references are to the Business and Professions Code unless otherwise indicated.

6. Section 4300 of the Code states:

(a) Every license issued may be suspended or revoked.

(b) The board shall discipline the holder of any license issued by the board, whose default has been entered or whose case has been heard by the board and found guilty, by any of the following methods:

(1) Suspending judgment.

(2) Placing him or her upon probation.

(3) Suspending his or her right to practice for a period not exceeding one year.

(4) Revoking his or her license.

(5) Taking any other action in relation to disciplining him or her as the board in its discretion may deem proper.

• • •

1 (e) The proceedings under this article shall be conducted in accordance with
2 Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of the
3 Government Code, and the board shall have all the powers granted therein. The
4 action shall be final, except that the propriety of the action is subject to review
5 by the superior court pursuant to Section 1094.5 of the Code of Civil Procedure.

6
7
8
9
10 7. Section 4300.1 of the Code states:

11 The expiration, cancellation, forfeiture, or suspension of a board-issued
12 license by operation of law or by order or decision of the board or a court of
13 law, the placement of a license on a retired status, or the voluntary surrender of
14 a license by a licensee shall not deprive the board of jurisdiction to commence
15 or proceed with any investigation of, or action or disciplinary proceeding
16 against, the licensee or to render a decision suspending or revoking the license.

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

8. Section 4022 of the Code states

Dangerous drug" or "dangerous device" means any drug or device unsafe
for self-use in humans or animals, and includes the following:

(a) Any drug that bears the legend: "Caution: federal law prohibits
dispensing without prescription," "Rx only," or words of similar import.

(b) Any device that bears the statement: "Caution: federal law restricts
this device to sale by or on the order of a _____," "Rx only," or words of
similar import, the blank to be filled in with the designation of the practitioner
licensed to use or order use of the device.

(c) Any other drug or device that by federal or state law can be lawfully
dispensed only on prescription or furnished pursuant to Section 4006."

9. Section 4040 of the Code states in part:

(a) "Prescription" means an oral, written, or electronic transmission order
that is both of the following:

(1) Given individually for the person or persons for whom ordered that
includes all of the following:

(A) The name or names and address of the patient or patients.

(B) The name and quantity of the drug or device prescribed and the
directions for use.

(C) The date of issue.

(D) Either rubber stamped, typed, or printed by hand or typeset, the
name, address, and telephone number of the prescriber, his or her license
classification, and his or her federal registry number, if a controlled
substance is prescribed.

///

1 (E) A legible, clear notice of the condition or purpose for which the
2 drug is being prescribed, if requested by the patient or patients.

3 (F) If in writing, signed by the prescriber issuing the order, or the
4 certified nurse-midwife, nurse practitioner, physician assistant, or
5 naturopathic doctor who issues a drug order pursuant to Section 2746.51,
6 2836.1, 3502.1, or 3640.5, respectively, or the pharmacist who issues a
7 drug order pursuant to either Section 4052.1 or 4052.2.

8 ...

9 (b) Notwithstanding subdivision (a), a written order of the prescriber for a
10 dangerous drug, except for any Schedule II controlled substance, that contains
11 at least the name and signature of the prescriber, the name and address of the
12 patient in a manner consistent with paragraph (2) of subdivision (a) of Section
13 11164 of the Health and Safety Code, the name and quantity of the drug
14 prescribed, directions for use, and the date of issue may be treated as a
15 prescription by the dispensing pharmacist as long as any additional information
16 required by subdivision (a) is readily retrievable in the pharmacy. In the event
17 of a conflict between this subdivision and Section 11164 of the Health and
18 Safety Code, Section 11164 of the Health and Safety Code shall prevail.

19 (c) "Electronic transmission prescription" includes both image and data
20 prescriptions. "Electronic image transmission prescription" means any
21 prescription order for which a facsimile of the order is received by a pharmacy
22 from a licensed prescriber. "Electronic data transmission prescription" means
23 any prescription order, other than an electronic image transmission prescription,
24 that is electronically transmitted from a licensed prescriber to a pharmacy.

25

26 10. Section 4071 of the Code states:

27 Notwithstanding any other provision of law, a prescriber may authorize his or
28 her agent on his or her behalf to orally or electronically transmit a prescription
to the furnisher. The furnisher shall make a reasonable effort to determine that
the person who transmits the prescription is authorized to do so and shall record
the name of the authorized agent of the prescriber who transmits the order.

11. Section 4076 of the Code states in part:

(a) A pharmacist shall not dispense any prescription except in a container
that meets the requirements of state and federal law and is correctly labeled
with all of the following:

(1) . . . either the manufacturer's trade name of the drug or the generic
name and the name of the manufacturer. Commonly used abbreviations may be
used. Preparations containing two or more active ingredients may be identified
by the manufacturer's trade name or the commonly used name or the principal
active ingredients.

(2) The directions for the use of the drug.

(3) The name of the patient or patients.

(4) The name of the prescriber . . .

1 (5) The date of issue.

2 (6) The name and address of the pharmacy, and prescription number or
3 other means of identifying the prescription.

4 (7) The strength of the drug or drugs dispensed.

5 (8) The quantity of the drug or drugs dispensed.

6 (9) The expiration date of the effectiveness of the drug dispensed.

7 (10) The condition for which the drug was prescribed if requested by the
8 patient and the condition is indicated on the prescription. . . .

9 12. Section 4110 of the Code states in part:

10 (a) No person shall conduct a pharmacy in the State of California unless
11 he or she has obtained a license from the board. A license shall be required for
12 each pharmacy owned or operated by a specific person. A separate license shall
13 be required for each of the premises of any person operating a pharmacy in
14 more than one location. The license shall be renewed annually. The board may,
15 by regulation, determine the circumstances under which a license may be
16 transferred. . . .

17 13. Section 4113 of the Code states in part:

18 (a) Every pharmacy shall designate a pharmacist-in-charge and, within 30
19 days thereof, shall notify the board in writing of the identity and license number
20 of that pharmacist and the date he or she was designated.

21 ...

22 (c) The pharmacist-in-charge shall be responsible for a pharmacy's
23 compliance with all state and federal laws and regulations pertaining to the
24 practice of pharmacy.

25

26 14. Section 4169 of the Code states in part:

27 (a) A person or entity may not do any of the following:

28 (1) Purchase, trade, sell, or transfer dangerous drugs or dangerous devices at
wholesale with a person or entity that is not licensed with the board as a
wholesaler or pharmacy.

...

(3) Purchase, trade, sell, or transfer dangerous drugs that the person knew or
reasonably should have known were misbranded, as defined in Section 111335
of the Health and Safety Code. . . .

///

///

1 15. Section 4127.1 of the Code states in part:

2 ...

3 (f) Adverse effects reported or potentially attributable to a pharmacy's sterile
4 drug product shall be reported to the board within 12 hours and immediately
5 reported to the MedWatch program of the federal Food and Drug
6 Administration.

7 ...

8 16. Section 4301 of the Code states in part:

9 The board shall take action against any holder of a license who is guilty
10 of unprofessional conduct or whose license has been procured by fraud or
11 misrepresentation or issued by mistake. Unprofessional conduct shall include,
12 but is not limited to, any of the following:

13 ...

14 (j) The violation of any of the statutes of this state, of any other state, or
15 of the United States regulating controlled substances and dangerous drugs.

16 ...

17 (o) Violating or attempting to violate, directly or indirectly, or assisting in
18 or abetting the violation of or conspiring to violate any provision or term of this
19 chapter or of the applicable federal and state laws and regulations governing
20 pharmacy, including regulations established by the board or by any other state
21 or federal regulatory agency. . . .

22 17. Section 11164 of the Health and Safety Code states in part:

23 Except as provided in Section 11167, no person shall prescribe a
24 controlled substance, nor shall any person fill, compound, or dispense a
25 prescription for a controlled substance, unless it complies with the requirements
26 of this section.

27 ...

28 (b)(1) Notwithstanding paragraph (1) of subdivision (a) of Section
11162.1, any controlled substance classified in Schedule III, IV, or V may be
dispensed upon an oral or electronically transmitted prescription, which shall be
produced in hard copy form and signed and dated by the pharmacist filling the
prescription or by any other person expressly authorized by provisions of the
Business and Professions Code. Any person who transmits, maintains, or
receives any electronically transmitted prescription shall ensure the security,
integrity, authority, and confidentiality of the prescription. . . .

29 18. Section 111330 of the Health and Safety Code states, "Any drug or device is
30 misbranded if its labeling is false or misleading in any particular."

1 19. Section 111335 of the Health and Safety Code states, "Any drug or device is
2 misbranded if its labeling or packaging does not conform to the requirements of Chapter 4
3 (commencing with Section 110290)."

4 20. Section 111340 of the Health and Safety Code states:

5 Any drug or device is misbranded unless it bears a label containing all of
6 the following information:

7 (a) The name and place of business of the manufacturer, packer, or
8 distributor.

9 (b) An accurate statement of the quantity of the contents in terms of
10 weight, measure, or numerical count.

11 Reasonable variations from the requirements of subdivision (b) shall be
12 permitted. Requirements for placement and prominence of the information and
13 exemptions as to small packages shall be established in accordance with
14 regulations adopted pursuant to Section 110380.

15 21. Section 111440 of the Health and Safety Code states, "It is unlawful for any person to
16 manufacture, sell, deliver, hold, or offer for sale any drug or device that is misbranded."

17 22. Section 111445 of the Health and Safety Code states: "It is unlawful for any person to
18 misbrand any drug or device.

19 23. Title 16, California Code of Regulations ("CCR"), section 1735 states in part:

20 (a) "Compounding" means any of the following activities occurring in a
21 licensed pharmacy, by or under the supervision of a licensed pharmacist,
22 pursuant to a prescription:

23 (1) Altering the dosage form or delivery system of a drug

24 (2) Altering the strength of a drug

25 (3) Combining components or active ingredients

26 (4) Preparing a drug product from chemicals or bulk drug substances

27

28 24. Title 16, CCR, section 1735.4 states:

 (a) In addition to the labeling information required under Business and
Professions Code section 4076, the label of a compounded drug product shall
contain the generic name(s) of the principal active ingredient(s).

 (b) A statement that the drug has been compounded by the pharmacy
shall be included on the container or on the receipt provided to the patient.

1 (c) Drug products compounded into unit-dose containers that are too
2 small or otherwise impractical for full compliance with subdivisions (a) and (b)
3 shall be labeled with at least the name(s) of the active ingredient(s),
4 concentration or strength, volume or weight, pharmacy reference or lot number,
5 and expiration date.

6 25. Title 16, CCR, section 1735.2 states in part:

7 ...

8 (h) Every compounded drug product shall be given an expiration date
9 representing the date beyond which, in the professional judgment of the
10 pharmacist performing or supervising the compounding, it should not be used.
11 This "beyond use date" of the compounded drug product shall not exceed 180
12 days from preparation or the shortest expiration date of any component in the
13 compounded drug product, unless a longer date is supported by stability studies
14 of finished drugs or compounded drug products using the same components and
15 packaging. Shorter dating than set forth in this subsection may be used if it is
16 deemed appropriate in the professional judgment of the responsible pharmacist.

17 ...

18 26. Title 16, CCR, section 1735.5 states in part:

19 ...

20 (c) The policy and procedure manual shall include the following

21 ...

22 (3) The procedures for maintaining, storing, calibrating, cleaning, and
23 disinfecting equipment used in compounding, and for training on these
24 procedures as part of the staff training and competency evaluation process.

25 ...

26 27. Title 16, CCR, section 1751.7 states in part:

27 ...

28 (c) Batch-produced sterile injectable drug products compounded from one or
more non-sterile ingredients shall be subject to documented end product testing
for sterility and pyrogens and shall be quarantined until the end product testing
confirms sterility and acceptable levels of pyrogens.

...

28 28. Title 16, CCR, section 1761 states in part:

(a) No pharmacist shall compound or dispense any prescription which
contains any significant error, omission, irregularity, uncertainty, ambiguity or
alteration. Upon receipt of any such prescription, the pharmacist shall contact
the prescriber to obtain the information needed to validate the prescription. ...

COST RECOVERY

29. Section 125.3 of the Code states, in pertinent part, that the Board may request the administrative law judge to direct a licensee found to have committed a violation or violations of the licensing act to pay a sum not to exceed the reasonable costs of the investigation and enforcement of the case.

DRUGS

30. Oxytocin, sold under the brand name Pitocin, is a dangerous drug pursuant to Business and Professions Code section 4022. It is used to induce labor.

31. Releana®, a brand name for human chorionic gonadotropin is a Schedule III controlled substance pursuant to Health and Safety Code section 11056(f)(32) and is a dangerous drug pursuant to Business and Professions Code section 4022.

32. Trimix is an injectible compounded product consisting of three active ingredients: alprostadil, papaverine and phenolamine, all of which are dangerous drugs pursuant to Business and Professions Code 4022. Trimix is used to treat erectile dysfunction.

33. Valium/Flexeril/lidocaine suppository is a compounded product containing a combination of the following ingredients: cyclobenzaprine (Flexeril), diazepam (Valium) and lidocaine. It is a Schedule IV controlled substance as designated by Health and Safety Code Section 11057(d)(9), and is a dangerous drug pursuant to Business and Professions Code section 4022. It is used as a muscle relaxant.

RELEANA® PRESCRIPTIONS

34. At all times mentioned herein, Respondent Schapiro was the PIC of Respondent California Pharmacy and Compounding Center (hereinafter "CPCC"). On or about November 4, 2010, the Board received a telephone complaint from J.S. alleging CPCC filled a prescription "without the dosage." On December 14, 2010, the Board received an anonymous complaint that CPCC was involved in the illegal practice of compounding and selling an oral preparation of human chorionic gonadotropin ("HCG"), which was being sold under the trade name of "Releana."

1 35. On or about January 11, 2011, an inspector for the Board conducted an inspection of
2 CPCC following the receipt of these complaints concerning the pharmacy, which is further
3 described below.

4 36. On or about August 20, 2010, a prescription was faxed to CPCC for J.S. for sixty
5 vaginal suppositories of Valium/Flexeril/lidocaine. The prescription appeared to be signed by
6 S.S., a physician's assistant. The prescription showed it was faxed from a fax machine with the
7 name and telephone number of J.S. to CPCC. CPCC filled the prescription on the same day
8 under prescription number RX 652991. CPCC dispensed twelve suppositories of a compounded
9 medication containing "cyclo/diaz/lido" (cyclobenzaprine/diazepam/lidocaine). A duplicate label
10 provided by Respondent Schapiro showed the drug dispensed was "cyclo/diaz/lido" 10/5/62.5 mg
11 suppository and the prescriber was identified as Dr. M.C., not S.S.

12 37. There was no notation that CPCC ensured the security, integrity and/or authority of
13 the prescription by verifying the prescription with the prescriber. Likewise, there was no notation
14 CPCC attempted to determine whether J.S. was authorized by PA S.S. to transmit the prescription
15 on behalf of PA S.S. nor that J.S. was so authorized by PA S.S.

16 38. During the inspection of CPCC on January 11, 2011, Respondent Schapiro explained
17 that CPCC reached an exclusive agreement with Millenium Medical Spa ("Millenium") to
18 compound Releana®. Millenium was located in Newport Beach, California and was not licensed
19 with the Board as a pharmacy or wholesaler in California. Millenium held the patent for
20 Releana®, a medication containing the human chorionic gonadotropin ("HCG") as an active
21 ingredient. HCG formulations are used to facilitate weight loss and body contouring. According
22 to Respondent Schapiro, Millenium was responsible for marketing Releana® and receiving orders
23 from physicians throughout the country for Respondent CPCC to fill. Millenium processed the
24 orders and invoiced the physicians. Millenium then e-mailed the order form and a "Prescription
25 Fill-in Form" to CPCC. The Prescription Fill-in Form contained prescriptions written for each
26 patient and is further described in paragraph 34(c), below.

27 39. According to Respondent Schapiro, after CPCC received a prescription for Releana®
28 by e-mail, CPCC processed the prescription, compounded the Releana® vehicle, which is a

1 proprietary formula, and packaged the HCG in a separate container. CPCC dispensed the
2 medication in a Ziploc bag with a prescription label with the patient's name, prescription number,
3 the instruction to "Use as directed by physician," the prescribing physician, the date dispensed
4 and the expiration date. Releana® was dispensed in the form of a small vial containing the HCG
5 powder and a larger bottle containing the Releana® vehicle, a buffered solution. The medication
6 was shipped to the prescribing physician's office where the medication was mixed by the
7 physician and the larger container was dispensed to the patient. Millenium paid CPCC for all
8 materials and dispensing fees.

9 40. In addition to physicians in California, Millenium sold Releana® to physicians in
10 Alabama, Arizona, Florida, Georgia, Hawaii, Iowa, Illinois, Indiana, Maryland, Missouri,
11 Mississippi, Nebraska, Nevada, New York, Ohio, Oklahoma, South Carolina, Texas, Virginia and
12 Washington. Respondent CPCC compounded the medication for dispensing to physicians in
13 these states.

14 41. On March 8, 2011, Board inspectors conducted further investigation of CPCC's
15 practice regarding dispensing Releana®. The process by which Releana® was ordered was as
16 follows:

17 a. The physician ordered Releana® from Millenium. The order form was faxed to
18 Millenium along with the prescriptions for Releana® written on a prescription form with the
19 Releana® logo.

20 b. The order was processed by Millenium. A packing slip was generated with the
21 quantity purchased, the payment method (credit card name) and the amount due from the
22 prescriber.

23 c. Millenium then e-mailed the following documents to CPCC:

24 i) the packing slip with Releana®'s logo for the quantity ordered and addressed to
25 the physician;

26 ii) an order form with the name, address and telephone number of the physician, the
27 description of the drug ("human chorionic gonadotropin proprietary formula") and the
28 quantity ordered; and,

1 iii) a Prescription Fill-in Form with the prescriber's information and two columns of
2 five boxes to fill in the patient's name, address, telephone number, the pre-printed
3 description of the drugs as "Human Chorionic Gonadotropin proprietary formula" and
4 quantity to either select from "[1], [2], or [3]" or to fill in. The prescription form did not
5 state the date each prescription was written nor the strength of the drug.

6 42. CPCC's Drug Recall Report for Releana® showed that CPCC dispensed 5958
7 prescriptions for Releana® from October 1, 2010 to March 8, 2011. Thirty patients from the
8 Drug Recall Report were randomly selected and their Patient Drug Histories from March 8, 2010
9 to March 8, 2011 and prescriptions for Releana® were reviewed by Board inspectors.

10 43. The Drug Histories and Releana® prescriptions for the following patients were
11 reviewed:

Patient initials	Prescriber's initials	Releana® Rx Number	Date dispensed
K.C.	D.T.	Not available ¹	Not available
G.D.	A.H.	623609	11/12/2009
E.T.	R.G.	672251	2/22/2011
M.W.	D.I.	662399	12/29/2010
M.F.	F.V.	662302	12/28/2010
D.G.	N.L.	650860	7/26/2010
A.K.	D.B.	655068	9/10/2010
H.M.	D.D.	652872	8/20/2010
G.M.	L.E.	655753	9/21/2010
B.C.	H.M.	661771	12/16/2010
P.C.	S.E.	635667	3/8/2010
Q.W.	S.B.	658717	11/1/2010

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27 ¹ According to K.C.'s Patient Drug History, seven prescriptions for Releana® were
28 dispensed for this patient. However, a sample Releana® prescription was not provided to the
 Board inspectors. A prescription for testosterone was provided instead.

Patient initials	Prescriber's initials	Releana® Rx Number	Date dispensed
L.P.	J.B.	658030	10/21/2010
L.D.	J.W.	658261	10/26/2010
V.F.	T.P.	670762	1/31/2011
M.E.	L.K.	632162	2/9/2010
K.D.	A.T.	660151	11/18/2010
B.F.	P.M.	645830	6/1/2010
T.F.	G.J.	657118	10/11/2010
C.C.	G.J.	657120	10/11/2010
D.C.	U.K.	647200	6/15/2010
J.B.	T.L.	656880	10/8/2010
S.B.	M.S.	656960	10/8/2010
A.A.	D.P.	631816	2/8/2010
A.B.	H.S.	633855	2/24/2010
D.A.	A.D.	660830	12/2/2010
B.A.	E.M.	634248	2/26/2010
J.A.	A.D.	660833	12/2/2010
P.A.	R.C.	670879	2/1/2011

44. A review of the original prescriptions revealed that the Releana® prescriptions for each patient were cut out from the prescription form sent by Millenium to CPCC and affixed to a blank telephone prescription pad. A date was stamped on the prescription pads that appeared to be the date the prescriptions were filled. The prescriptions contained the name and address of the patient, the pre-printed drug name "human chorionic gonadotropin proprietary formula" and the provider's signature. The prescriptions did not have the strength of HCG and the quantity prescribed was specified in units of "1", "2" or "3." There were no notations on the prescriptions indicating the pharmacist verified the prescriptions with the physicians since the prescriptions

1 were electronically received from Millenium instead of from the prescribing physicians. Many of
2 the prescribing physicians were located out of the state of California.

3 45. Affixed to the prescriptions were the prescription backer labels. The backer labels
4 indicated the prescription number assigned, the patient's name, the physician's name, the drug
5 dispensed (Releana - Chorionic Gonadotropin), the quantity, the instruction "Use as Directed by
6 Physician," and notations with CPCC's compounding lot number for the product dispensed and
7 the pharmacist's initials. The prescription backer label did not state the concentration, volume or
8 weight of the active ingredient nor the quantity of the drug dispensed. Prescriptions labels that
9 were duplicates of the prescription labels on the drug containers were also obtained. The
10 duplicate prescription labels did not state the concentration, volume or weight of the active
11 ingredient nor the quantity of the drug dispensed.

12 **FIRST CAUSE FOR DISCIPLINE**

13 **AGAINST CALIFORNIA PHARMACY AND COMPOUNDING CENTER**

14 **AND DAVID JOSEPH SCHAPIRO**

15 **(Violation of Pharmacy Law - Failure to Ensure Integrity of Prescription)**

16 46. Respondents CPCC and Schapiro are subject to discipline pursuant to Code section
17 4301, subdivisions (j) and (o), for violating Code section 4071 and Health and Safety Code
18 section 11164 in that Respondents failed to ensure the security, integrity and/or authority of J.S.'s
19 prescription by failing to verify the prescription with the prescribing physician, as more fully set
20 forth in paragraphs 34 - 45, which are incorporated by this reference as though set forth in full
21 herein.

22 **SECOND CAUSE FOR DISCIPLINE**

23 **AGAINST CALIFORNIA PHARMACY AND COMPOUNDING CENTER**

24 **AND DAVID JOSEPH SCHAPIRO**

25 **(Violation of Pharmacy Law - Erroneous and Uncertain Prescriptions)**

26 47. Respondents CPCC and Schapiro are subject to discipline pursuant to Code section
27 4301, subdivisions (j) and (o), for violating Code section 4040; title 16, CCR, section 1761; and,
28 Health and Safety Code section 11164. Respondents compounded and/or dispensed prescriptions

1 for Releana® containing significant errors, omissions, irregularities and/or uncertainties as more
2 fully set forth in paragraphs 34 – 45, which are incorporated by this reference as though set forth
3 in full herein, and as follows:

4 a. The prescriptions for Releana® did not specify the quantity to dispense, the directions
5 for use and the date the prescription was issued.

6 b. The electronically transmitted prescriptions for Releana® were not valid in that the
7 prescriptions were received by CPCC from Millenium instead of the prescriber and were not
8 verified with the prescribing physician by the CPCC.

9 c. The electronically transmitted prescriptions for Releana® that were produced into a
10 hard copy did not bear the date the prescription was transcribed or the signature of the
11 transcribing pharmacist.

12 d. The electronically transmitted prescriptions for Releana® did not have the name of
13 the person at the prescriber's office who transmitted the prescriptions.

14 **THIRD CAUSE FOR DISCIPLINE**

15 **AGAINST CALIFORNIA PHARMACY AND COMPOUNDING CENTER**

16 **AND DAVID JOSEPH SCHAPIRO**

17 **(Selling to Unlicensed Entity)**

18 48. Respondents CPCC and Schapiro are subject to discipline pursuant to Code section
19 4301, subdivision (o) for violation of section 4169, subdivision (a)(1), for selling dangerous drugs
20 to an entity not licensed by the Board. Respondents compounded and sold Releana® to
21 Millenium, an entity not licensed by the Board as a pharmacy or wholesaler in California, as is
22 more fully set forth in paragraphs 34 – 45, which are incorporated by this reference as though set
23 forth in full herein.

24 ///

25 ///

26 ///

27 ///

28 ///

1 **FOURTH CAUSE FOR DISCIPLINE**

2 **AGAINST CALIFORNIA PHARMACY AND COMPOUNDING CENTER**

3 **AND DAVID JOSEPH SCHAPIRO**

4 **(Selling Misbranded Drugs)**

5 49. Respondents CPCC and Schapiro are subject to discipline pursuant to Code sections
6 4301, subdivisions (j) and (o) for violation of section 4169, subdivision (a)(3), and Health and
7 Safety Code sections 11130, 111440 and 11340, for selling, delivering, transferring, holding or
8 offering for sale, any drug that Respondents knew or should reasonably have known were
9 misbranded. The Releana® drugs were misbranded in that the label affixed to each individual
10 container of Releana® powder and Releana® vehicle, did not specify the name and address of the
11 manufacturer, packer or distributor and they did not specify the quantity of the contents of each of
12 the two containers sold in terms of weight or measure, as is more fully set forth in paragraphs 34-
13 45, which are incorporated by this reference as though set forth in full herein.

14 **FIFTH CAUSE FOR DISCIPLINE**

15 **AGAINST CALIFORNIA PHARMACY AND COMPOUNDING CENTER**

16 **AND DAVID JOSEPH SCHAPIRO**

17 **(Dispensing Incorrectly Labeled Prescriptions)**

18 50. Respondents CPCC and Schapiro are subject to discipline pursuant to Code section
19 4301, subdivision (o) for violation of section 4076, subdivision (a)(7) and (8) and title 16, CCR,
20 1735.4, for dispensing incorrectly labeled Releana® prescriptions in that Respondents dispensed
21 Releana® with prescription labels that did not state the concentration or strength of the active
22 ingredient nor the quantity of the drug dispensed, either in volume, weight or numerical count, as
23 is more fully set forth in paragraphs 34 -- 45, which are incorporated by this reference as though
24 set forth in full herein.

25 ///

26 ///

27 ///

28 ///

SIXTH CAUSE FOR DISCIPLINE
AGAINST CALIFORNIA PHARMACY AND COMPOUNDING CENTER
AND DAVID JOSEPH SCHAPIRO

(Aiding or Abetting Millenium in Sale of Controlled Substances)

51. Respondents CPCC and Schapiro are subject to discipline pursuant to Code section 4301, subdivision (o) for assisting in or abetting the violation of Code section 4110 by Millenium, in that Millenium sold Releana® to physicians in California, among other states, without having a license as a pharmacy or wholesaler in the State of California, as more fully set forth in paragraphs 34 – 45 and incorporated by this reference as though set forth in full herein.

COMPOUNDED CARBOXYMETHYLCELLULOSE 0.2%

52. On January 28, 2015, an annual renewal sterile compounding inspection was conducted at Respondent pharmacy. As part of the inspection, the compounding record for prescription #719944 (Rx #719944) made on January 15, 2015 was reviewed. The original compounding records with integrated master formula for compounding carboxymethylcellulose 0.2% preservative free eye drops were reviewed. The pharmacy's policies and procedures for cleaning the autoclave to compound Rx #719944 and the convection oven next to the autoclave were requested but were not available for review during the inspection.

53. Sodium carboxymethylcellulose ("CMC") powder, lot # 14C03-U02-017876 was the active ingredient used to compound Rx #719944. The compounding record for carboxymethylcellulose 0.2% erroneously stated that the expiration date of CMC powder, lot # 14C03-U02-017876, was January 15, 2016, when the correct expiration date was January 15, 2015.

54. The expiration date assigned to the compounded drug Rx #719944 was March 1, 2015, 45 days after the expiration of CMC powder, which was the active ingredient used to compound Rx #719944.

///

///

///

1 **SEVENTH CAUSE FOR DISCIPLINE**

2 **AGAINST CALIFORNIA PHARMACY AND COMPOUNDING CENTER**

3 **AND DAVID JOSEPH SCHAPIRO**

4 **(No Policy and Procedures for Autoclave and Convection Oven)**

5 55. Respondents CPCC and Schapiro are subject to discipline pursuant to Code section
6 4301, subdivision (o) in conjunction with 16, title CCR, section 1735.5(a) for failing to maintain
7 a written policy and procedure manual that includes the procedures for maintaining, storing,
8 calibrating, cleaning, and disinfecting the autoclave and convection oven, equipment used in
9 compounding, as more fully set forth in paragraph 52 above and which is incorporated by this
10 reference as though set forth in full herein.

11 **EIGHTH CAUSE FOR DISCIPLINE**

12 **AGAINST CALIFORNIA PHARMACY AND COMPOUNDING CENTER**

13 **AND DAVID JOSEPH SCHAPIRO**

14 **(Erroneous Expiration Date Assigned)**

15 56. Respondents CPCC and Schapiro are subject to discipline pursuant to Code section
16 4301, subdivision (o) in conjunction with 16, title CCR, section 1735.2(h), for assigning an
17 erroneous expiration date to Rx #719944 that exceeded the shortest expiration date of any
18 component in the compounded drug product, as more fully set forth in paragraphs 52-54 above
19 and which are incorporated by this reference as though set forth in full herein.

20 **ADVERSE EVENT REPORT**

21 57. On April 1, 2015, the Board was notified of an adverse event pertaining to an Avastin
22 syringe compounded by Respondents. On July and November, 2014, O.B. received Avastin
23 injections in her eye at her doctor's office. The Avastin injection was a compounded sterile
24 product obtained by O.B.'s physician from Respondent. It was used to treat wet age-related
25 macular degeneration.

26 58. On February 2, 2015, O.B. received another Avastin injection compounded by
27 Respondents (lot number B120714). On March 4, 2015, O.B. notified her doctor that she had an
28

1 eye infection. On March 6, 2015, O.B.'s doctor called Respondents about O.B.'s eye infection
2 and her use of Avastin.

3 59. On March 16, 2015, O.B.'s doctor's office notified Respondents that a culture of the
4 patient was done and the results were negative.

5 **NINTH CAUSE FOR DISCIPLINE**

6 **AGAINST CALIFORNIA PHARMACY AND COMPOUNDING CENTER**

7 **AND DAVID JOSEPH SCHAPIRO**

8 **(Failure to Report Adverse Event to Board Within 12 Hours)**

9 60. Respondents CPCC and Schapiro are subject to discipline pursuant to Code section
10 4301, subdivision (o) in conjunction with Code section 4127.1(f) in that Respondents failed to
11 report the adverse event regarding O.B. to the Board within 12 hours, as more fully set forth in
12 paragraphs 57-59 above and which are incorporated by this reference as though set forth in full
13 herein.

14 **JULY 24, 2015 INSPECTION**

15 61. On July 24, 2015, an inspector for the Board conducted an inspection of CPCC
16 following the receipt of a copy of a Warning Letter issued by the Food and Drug Administration
17 (WL# 23-15) to CPCC on June 17, 2015.

18 62. During the inspection, the Board inspector observed batch oxytocin, a compounded
19 product, in CPCC's refrigerator where they were "quarantined" before they are released into the
20 market. The oxytocin was to be used intranasally in an investigational study of individuals with
21 high functioning autism. The oxytocin was labeled as follows: Oxytocin 360u/ml
22 lot#B063015R, expiration 06/01/16 and Oxytocin 1200u/ml lot#B050815R, expiration 05/02/16.
23 The "beyond use date" ("BUD") assigned to these products of almost one year exceeded the
24 mandatory compounding limitation of 180 days from preparation or the shortest expiration date of
25 any component in the compounded drug product. Respondent Schapiro explained that CPCC has
26 document to justify the extended BUD assigned to these products.

27 63. The Board inspector requested stability studies to justify the extended BUD given to
28 the oxytocin. Respondent provided a study performed by the Department of Pharmacy of the

1 University of California, San Diego ("UCSD study"). The UCSD study did not comply with the
2 Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
3 ("ICH").² The ICH requires rigorous studies under three major categories, chemical, physical
4 and microbiological. The UCSD study did not record the physical observation of the oxytocin
5 used over the period of the test, nor was there any documentation or record of the chemical
6 stability or chemical composition of the active pharmaceutical ingredients ("API") as they reacted
7 with the excipients. Furthermore, Respondent was compounding oxytocin 360u/ml, but the
8 UCSD study only measured and recorded the potency of the API in oxytocin 60u/ml and 120u/ml
9 during the period of testing.

10 64. The Board inspector discussed the inadequacies of the UCSD study with Respondent
11 Schapiro and on September 1, 2015, the inspector requested a copy of the full stability study done
12 by UCSD's laboratory.

13 65. On or about September 19, 2015, the Board inspector received a full copy of the
14 oxytocin stability study, which was the same study presented during the inspection on July 24,
15 2015. The study did not record the physical appearance of the compounded products at various
16 time points and did not record how the API interacted with the excipients. The UCSD study did
17 not discuss whether a sterility study had been done. The UCSD study only focused on the
18 potency of the API.

19 66. A review of CPCC's qualitative and quantitative testing reports received by the Board
20 on July 24, 2015 showed that CPCC was not testing all end products from non-sterile batches that
21 were compounded for sterility and endotoxin. For example, CPCC performed sterility testing of
22 the individual components that made up Trimix but not the resultant Trimix end product that was
23 dispensed to patients.

24
25
26 ² The objective of ICH is to increase international harmonisation of technical requirements
27 to ensure that safe, effective, and high quality medicines are developed and registered in the most
28 efficient and cost-effective manner. These activities have been undertaken to promote public
health, prevent unnecessary duplication of clinical trials in humans, and minimize the use of
animal testing without compromising safety and effectiveness. (www.ich.org/about/faqs.html.)

1 67. The individual compounded ingredients used in the formulation of Trimix, its
2 byproducts and the resultant Trimix product were not tested for endotoxin even though the Trimix
3 product was made from non-sterile products. Between January 1, 2013 and May 31, 2014, CPCC
4 compounded 49 batches of Trimix from non-sterile bulk ingredients. These 49 batches of Trimix
5 were not tested for pyrogens as required. They were not quarantined until end product testing
6 confirmed sterility and acceptable levels of pyrogens. Instead, Respondents Schapiro, Truong
7 and Han authorized the release of these batches for dispensing to patients. CPCC dispensed 924
8 prescriptions of Trimix between January 1, 2013 and May 31, 2014.

9 **TENTH CAUSE FOR DISCIPLINE**

10 **AGAINST CALIFORNIA PHARMACY AND COMPOUNDING CENTER**

11 **AND DAVID JOSEPH SCHAPIRO**

12 **(Erroneous Expiration Date Assigned)**

13 68. Respondents CPCC and Schapiro are subject to discipline pursuant to Code section
14 4301, subdivision (o) in conjunction with 16, title CCR, section 1735.2(h), for assigning
15 erroneous expiration dates to compounded oxytocin. Between April 1, 2012 and September 1,
16 2015, Respondents compounded oxytocin 120u/ml and 360u/ml and assigned a BUD of one
17 year without adequate supporting stability studies to justify the extended BUD, as more fully set
18 forth in paragraphs 61 – 66 above and incorporated by this reference as though set forth in full.

19 **ELEVENTH CAUSE FOR DISCIPLINE**

20 **AGAINST CALIFORNIA PHARMACY AND COMPOUNDING CENTER**

21 **AND DAVID JOSEPH SCHAPIRO**

22 **(Failure to Conduct and Document End Product Testing and Failure to Quarantine)**

23 69. Respondents CPCC and Schapiro are subject to discipline pursuant to Code section
24 4301, subdivision (o) in conjunction with 16, title CCR, section 1751.7(c), for failure to test and
25 document end product testing of 49 batches of Trimix for sterility and pyrogens and failure to
26 quarantine until the end product testing confirmed sterility and acceptable levels of pyrogens as
27 more fully set forth in paragraphs 61 – 66 above and incorporated by this reference as though set
28 forth in full.

1

2

3

△

3

11

12

1.

1.

i

2

2

2

2

24

6. Taking such other and further action as deemed necessary and proper.

DATED:

5/2/16

Virginia Herold

VIRGINIA HEROLD

Executive Officer

Board of Pharmacy

Department of Consumer Affairs

State of California

Complainant

SD2013805160/81269824.doc

1 KAMALA D. HARRIS
Attorney General of California
2 JAMES M. LEDAKIS
Supervising Deputy Attorney General
3 MARICHELLE S. TAHIMIC
Deputy Attorney General
4 State Bar No. 147392
110 West "A" Street, Suite 1100
5 San Diego, CA 92101
P.O. Box 85266
6 San Diego, CA 92186-5266
Telephone: (619) 645-3154
7 Facsimile: (619) 645-2061
Attorneys for Complainant

8
9 **BEFORE THE**
BOARD OF PHARMACY
10 **DEPARTMENT OF CONSUMER AFFAIRS**
STATE OF CALIFORNIA

11 In the Matter of the Accusation Against:

Case No. 4628

12 **CALIFORNIA PHARMACY AND**
13 **COMPOUNDING CENTER**

14 4000 Birch Street, Suite 120
Newport Beach, CA 92660

ACCUSATION

15 Pharmacy Permit No. PHY 49828
16 Sterile Compounding License No. LSC
99542

17 and

18 **DAVID JOSEPH SCHAPIRO**

19 14501 Larch Avenue
Irvine, CA 92606

20 Pharmacist License No. RPH 26704

21 Respondents.

22
23 Complainant alleges:

24 **PARTIES**

25 1. Virginia Herold (Complainant) brings this Accusation solely in her official capacity
26 as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.

27 2. On or about April 1, 2009, the Board of Pharmacy issued Pharmacy Permit Number
28 PHY 49828 to California Pharmacy and Compounding Center (Respondent). The Pharmacy

1 Permit was in full force and effect at all times relevant to the charges brought herein and will
2 expire on April 1, 2014, unless renewed.

3 3. On or about April 2, 2009, the Board of Pharmacy issued Sterile Compounding
4 License Number LSC 99542 to California Pharmacy and Compounding Center (Respondent).
5 The Sterile Compounding License was in full force and effect at all times relevant to the charges
6 brought herein and will expire on April 1, 2014, unless renewed.

7 4. On or about July 16, 1970, the Board of Pharmacy issued Pharmacist License
8 Number RPH 26704 to David Joseph Schapiro (Respondent). The Pharmacist License was in full
9 force and effect at all times relevant to the charges brought herein and will expire on July 31,
10 2013, unless renewed. Respondent Schapiro was the Pharmacist-In-Charge ("PIC") of CPCC and
11 has been the PIC since April 1, 2009.

12 JURISDICTION

13 5. This Accusation is brought before the Board of Pharmacy (Board), Department of
14 Consumer Affairs, under the authority of the following laws. All section references are to the
15 Business and Professions Code unless otherwise indicated.

16 6. Section 4300 of the Code states:

17 (a) Every license issued may be suspended or revoked.

18 (b) The board shall discipline the holder of any license issued by the board,
19 whose default has been entered or whose case has been heard by the board and
found guilty, by any of the following methods:

20 (1) Suspending judgment.

21 (2) Placing him or her upon probation.

22 (3) Suspending his or her right to practice for a period not exceeding one
23 year.

24 (4) Revoking his or her license.

25 (5) Taking any other action in relation to disciplining him or her as the
board in its discretion may deem proper.

26 ...

27 (e) The proceedings under this article shall be conducted in accordance with
28 Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of the
Government Code, and the board shall have all the powers granted therein. The

1 action shall be final, except that the propriety of the action is subject to review
2 by the superior court pursuant to Section 1094.5 of the Code of Civil Procedure.

3 7. Section 4300.1 of the Code states:

4 The expiration, cancellation, forfeiture, or suspension of a board-issued
5 license by operation of law or by order or decision of the board or a court of
6 law, the placement of a license on a retired status, or the voluntary surrender of
7 a license by a licensee shall not deprive the board of jurisdiction to commence
8 or proceed with any investigation of, or action or disciplinary proceeding
9 against, the licensee or to render a decision suspending or revoking the license.

10 **STATUTORY AND REGULATORY PROVISIONS**

11 8. Section 4022 of the Code states

12 Dangerous drug" or "dangerous device" means any drug or device unsafe
13 for self-use in humans or animals, and includes the following:

14 (a) Any drug that bears the legend: "Caution: federal law prohibits
15 dispensing without prescription," "Rx only," or words of similar import.

16 (b) Any device that bears the statement: "Caution: federal law restricts
17 this device to sale by or on the order of a _____," "Rx only," or words of
18 similar import, the blank to be filled in with the designation of the practitioner
19 licensed to use or order use of the device.

20 (c) Any other drug or device that by federal or state law can be lawfully
21 dispensed only on prescription or furnished pursuant to Section 4006."

22 9. Section 4040 of the Code states in part:

23 (a) "Prescription" means an oral, written, or electronic transmission order
24 that is both of the following:

25 (1) Given individually for the person or persons for whom ordered that
26 includes all of the following:

27 (A) The name or names and address of the patient or patients.

28 (B) The name and quantity of the drug or device prescribed and the
directions for use.

(C) The date of issue.

(D) Either rubber stamped, typed, or printed by hand or typeset, the
name, address, and telephone number of the prescriber, his or her license
classification, and his or her federal registry number, if a controlled
substance is prescribed.

(E) A legible, clear notice of the condition or purpose for which the
drug is being prescribed, if requested by the patient or patients.

(F) If in writing, signed by the prescriber issuing the order, or the
certified nurse-midwife, nurse practitioner, physician assistant, or

1 naturopathic doctor who issues a drug order pursuant to Section 2746.51,
2 2836.1, 3502.1, or 3640.5, respectively, or the pharmacist who issues a
3 drug order pursuant to either Section 4052.1 or 4052.2.

4 (b) Notwithstanding subdivision (a), a written order of the prescriber for a
5 dangerous drug, except for any Schedule II controlled substance, that contains
6 at least the name and signature of the prescriber, the name and address of the
7 patient in a manner consistent with paragraph (2) of subdivision (a) of Section
8 11164 of the Health and Safety Code, the name and quantity of the drug
9 prescribed, directions for use, and the date of issue may be treated as a
10 prescription by the dispensing pharmacist as long as any additional information
11 required by subdivision (a) is readily retrievable in the pharmacy. In the event
12 of a conflict between this subdivision and Section 11164 of the Health and
13 Safety Code, Section 11164 of the Health and Safety Code shall prevail.

14 (c) "Electronic transmission prescription" includes both image and data
15 prescriptions. "Electronic image transmission prescription" means any
16 prescription order for which a facsimile of the order is received by a pharmacy
17 from a licensed prescriber. "Electronic data transmission prescription" means
18 any prescription order, other than an electronic image transmission prescription,
19 that is electronically transmitted from a licensed prescriber to a pharmacy.

20 10. Section 4071 of the Code states:

21 Notwithstanding any other provision of law, a prescriber may authorize his or
22 her agent on his or her behalf to orally or electronically transmit a prescription
23 to the furnisher. The furnisher shall make a reasonable effort to determine that
24 the person who transmits the prescription is authorized to do so and shall record
25 the name of the authorized agent of the prescriber who transmits the order.

26 11. Section 4076 of the Code states in part:

27 (a) A pharmacist shall not dispense any prescription except in a container
28 that meets the requirements of state and federal law and is correctly labeled
with all of the following:

(1) ... either the manufacturer's trade name of the drug or the generic
name and the name of the manufacturer. Commonly used abbreviations may be
used. Preparations containing two or more active ingredients may be identified
by the manufacturer's trade name or the commonly used name or the principal
active ingredients.

(2) The directions for the use of the drug.

(3) The name of the patient or patients.

(4) The name of the prescriber . . .

(5) The date of issue.

(6) The name and address of the pharmacy, and prescription number or

other means of identifying the prescription.

(7) The strength of the drug or drugs dispensed.

(8) The quantity of the drug or drugs dispensed.

(9) The expiration date of the effectiveness of the drug dispensed.

(10) The condition for which the drug was prescribed if requested by the patient and the condition is indicated on the prescription. . . .

12. Section 4110 of the Code states in part:

(a) No person shall conduct a pharmacy in the State of California unless he or she has obtained a license from the board. A license shall be required for each pharmacy owned or operated by a specific person. A separate license shall be required for each of the premises of any person operating a pharmacy in more than one location. The license shall be renewed annually. The board may, by regulation, determine the circumstances under which a license may be transferred. . . .

13. Section 4113 of the Code states in part:

(a) Every pharmacy shall designate a pharmacist-in-charge and, within 30 days thereof, shall notify the board in writing of the identity and license number of that pharmacist and the date he or she was designated.

...

(c) The pharmacist-in-charge shall be responsible for a pharmacy's compliance with all state and federal laws and regulations pertaining to the practice of pharmacy.

....

14. Section 4169 of the Code states in part:

(a) A person or entity may not do any of the following:

(1) Purchase, trade, sell, or transfer dangerous drugs or dangerous devices at wholesale with a person or entity that is not licensed with the board as a wholesaler or pharmacy.

...

(3) Purchase, trade, sell, or transfer dangerous drugs that the person knew or reasonably should have known were misbranded, as defined in Section 111335 of the Health and Safety Code. . . .

15. Section 4301 of the Code states in part:

The board shall take action against any holder of a license who is guilty of unprofessional conduct or whose license has been procured by fraud or misrepresentation or issued by mistake. Unprofessional conduct shall include, but is not limited to, any of the following:

1
2 (j) The violation of any of the statutes of this state, of any other state, or
3 of the United States regulating controlled substances and dangerous drugs.

4
5 (o) Violating or attempting to violate, directly or indirectly, or assisting in
6 or abetting the violation of or conspiring to violate any provision or term of this
chapter or of the applicable federal and state laws and regulations governing
pharmacy, including regulations established by the board or by any other state
or federal regulatory agency. . . .

7 16. Section 11164 of the Health and Safety Code states in part:

8 Except as provided in Section 11167, no person shall prescribe a
9 controlled substance, nor shall any person fill, compound, or dispense a
10 prescription for a controlled substance, unless it complies with the requirements
of this section.

11
12 (b)(1) Notwithstanding paragraph (1) of subdivision (a) of Section
13 11162.1, any controlled substance classified in Schedule III, IV, or V may be
dispensed upon an oral or electronically transmitted prescription, which shall be
14 produced in hard copy form and signed and dated by the pharmacist filling the
prescription or by any other person expressly authorized by provisions of the
15 Business and Professions Code. Any person who transmits, maintains, or
receives any electronically transmitted prescription shall ensure the security,
integrity, authority, and confidentiality of the prescription. . . .

16 17. Section 111330 of the Health and Safety Code states, "Any drug or device is
17 misbranded if its labeling is false or misleading in any particular."

18 18. Section 111335 of the Health and Safety Code states, "Any drug or device is
19 misbranded if its labeling or packaging does not conform to the requirements of Chapter 4
20 (commencing with Section 110290)."

21 19. Section 111340 of the Health and Safety Code states:

22 Any drug or device is misbranded unless it bears a label containing all of
23 the following information:

24 (a) The name and place of business of the manufacturer, packer, or
distributor.

25 (b) An accurate statement of the quantity of the contents in terms of
26 weight, measure, or numerical count.

27 Reasonable variations from the requirements of subdivision (b) shall be
permitted. Requirements for placement and prominence of the information and
28 exemptions as to small packages shall be established in accordance with
regulations adopted pursuant to Section 110380.

20. Section 111440 of the Health and Safety Code states, "It is unlawful for any person to manufacture, sell, deliver, hold, or offer for sale any drug or device that is misbranded."

21. Section 111445 of the Health and Safety Code states: "It is unlawful for any person to misbrand any drug or device."

22. Title 16, California Code of Regulations (“CCR”), section 1735 states in part:

(a) "Compounding" means any of the following activities occurring in a licensed pharmacy, by or under the supervision of a licensed pharmacist, pursuant to a prescription:

(1) Altering the dosage form or delivery system of a drug

(2) Altering the strength of a drug

(3) Combining components or active ingredients

(4) Preparing a drug product from chemicals or bulk drug substances

• • • •

23. Title 16, CCR, section 1735.4 states:

(a) In addition to the labeling information required under Business and Professions Code section 4076, the label of a compounded drug product shall contain the generic name(s) of the principal active ingredient(s).

(b) A statement that the drug has been compounded by the pharmacy shall be included on the container or on the receipt provided to the patient.

(c) Drug products compounded into unit-dose containers that are too small or otherwise impractical for full compliance with subdivisions (a) and (b) shall be labeled with at least the name(s) of the active ingredient(s), concentration or strength, volume or weight, pharmacy reference or lot number, and expiration date.

24. Title 16, CCR, section 1761 states in part:

(a) No pharmacist shall compound or dispense any prescription which contains any significant error, omission, irregularity, uncertainty, ambiguity or alteration. Upon receipt of any such prescription, the pharmacist shall contact the prescriber to obtain the information needed to validate the prescription.

• • •

COST RECOVERY

25. Section 125.3 of the Code states, in pertinent part, that the Board may request the administrative law judge to direct a licensee found to have committed a violation or violations of

1 the licensing act to pay a sum not to exceed the reasonable costs of the investigation and
2 enforcement of the case.

3 DRUGS

4 26. Releana®, a brand name for human chorionic gonadotropin is a Schedule III
5 controlled substance pursuant to Health and Safety Code section 11056(f)(32) and is a dangerous
6 drug pursuant to Business and Professions Code section 4022.

7 27. Valium/Flexeril/lidocaine suppository is a compounded product containing a
8 combination of the following ingredients: cyclobenzaprine (Flexeril), diazepam (Valium) and
9 lidocaine. It is a Schedule IV controlled substance as designated by Health and Safety Code
10 Section 11057(d)(9), and is a dangerous drug pursuant to Business and Professions Code section
11 4022. It is used as a muscle relaxant.

12 FACTS

13 28. At all times mentioned herein, Respondent Schapiro was the PIC of Respondent
14 California Pharmacy and Compounding Center (hereinafter "CPCC"). On or about November 4,
15 2010, the Board received a telephone complaint from J.S. alleging CPCC filled a prescription
16 "without the dosage." On December 14, 2010, the Board received an anonymous complaint that
17 CPCC was involved in the illegal practice of compounding and selling an oral preparation of
18 human chorionic gonadotropin ("HCG"), which was being sold under the trade name of
19 "Releana."

20 29. On or about January 11, 2011, an inspector for the Board conducted an inspection of
21 CPCC following the receipt of these complaints concerning the pharmacy, which is further
22 described below.

23 30. On or about August 20, 2010, a prescription was faxed to CPCC for J.S. for sixty
24 vaginal suppositories of Valium/Flexeril/lidocaine. The prescription appeared to be signed by
25 S.S., a physician's assistant. The prescription showed it was faxed from a fax machine with the
26 name and telephone number of J.S. to CPCC. CPCC filled the prescription on the same day
27 under prescription number RX 652991. CPCC dispensed twelve suppositories of a compounded
28 medication containing "cyclo/diaz/lido" (cyclobenzaprine/diazepam/lidocaine). A duplicate label

1 provided by Respondent Schapiro showed the drug dispensed was "cyclo/diaz/lido" 10/5/62.5 mg
2 suppository and the prescriber was identified as Dr. M.C., not S.S.

3 31. There was no notation that CPCC ensured the security, integrity and/or authority of
4 the prescription by verifying the prescription with the prescriber. Likewise, there was no notation
5 CPCC attempted to determine whether J.S. was authorized by PA S.S. to transmit the prescription
6 on behalf of PA S.S. nor that J.S. was so authorized by PA S.S.

7 32. During the inspection of CPCC on January 11, 2011, Respondent Schapiro explained
8 that CPCC reached an exclusive agreement with Millenium Medical Spa ("Millenium") to
9 compound Releana®. Millenium was located in Newport Beach, California and was not licensed
10 with the Board as a pharmacy or wholesaler in California. Millenium held the patent for
11 Releana®, a medication containing the human chorionic gonadotropin ("HCG") as an active
12 ingredient. HCG formulations are used to facilitate weight loss and body contouring. According
13 to Respondent Schapiro, Millenium was responsible for marketing Releana® and receiving orders
14 from physicians throughout the country for Respondent CPCC to fill. Millenium processed the
15 orders and invoiced the physicians. Millenium then e-mailed the order form and a "Prescription
16 Fill-in Form" to CPCC. The Prescription Fill-in Form contained prescriptions written for each
17 patient and is further described in paragraph 34(c), below.

18 33. According to Respondent Schapiro, after CPCC received a prescription for Releana®
19 by e-mail, CPCC processed the prescription, compounded the Releana® vehicle, which is a
20 proprietary formula, and packaged the HCG in a separate container. CPCC dispensed the
21 medication in a Ziploc bag with a prescription label with the patient's name, prescription number,
22 the instruction to "Use as directed by physician," the prescribing physician, the date dispensed
23 and the expiration date. Releana® was dispensed in the form of a small vial containing the HCG
24 powder and a larger bottle containing the Releana® vehicle, a buffered solution. The medication
25 was shipped to the prescribing physician's office where the medication was mixed by the
26 physician and the larger container was dispensed to the patient. Millenium paid CPCC for all
27 materials and dispensing fees.
28

1 34. In addition to physicians in California, Millenium sold Releana® to physicians in
2 Alabama, Arizona, Florida, Georgia, Hawaii, Iowa, Illinois, Indiana, Maryland, Missouri,
3 Mississippi, Nebraska, Nevada, New York, Ohio, Oklahoma, South Carolina, Texas, Virginia and
4 Washington. Respondent CPCC compounded the medication for dispensing to physicians in
5 these states.

6 35. On March 8, 2011, Board inspectors conducted further investigation of CPCC's
7 practice regarding dispensing Releana®. The process by which Releana® was ordered was as
8 follows:

9 a. The physician ordered Releana® from Millenium. The order form was faxed to
10 Millenium along with the prescriptions for Releana® written on a prescription form with the
11 Releana® logo.

12 b. The order was processed by Millenium. A packing slip was generated with the
13 quantity purchased, the payment method (credit card name) and the amount due from the
14 prescriber.

15 c. Millenium then e-mailed the following documents to CPCC:

16 i) the packing slip with Releana®'s logo for the quantity ordered and addressed to
17 the physician;

18 ii) an order form with the name, address and telephone number of the physician, the
19 description of the drug ("human chorionic gonadotropin proprietary formula") and the
20 quantity ordered; and,

21 iii) a Prescription Fill-in Form with the prescriber's information and two columns of
22 five boxes to fill in the patient's name, address, telephone number, the pre-printed
23 description of the drugs as "Human Chorionic Gonadotropin proprietary formula" and
24 quantity to either select from "[1], [2], or [3]" or to fill in. The prescription form did not
25 state the date each prescription was written nor the strength of the drug.

26 36. CPCC's Drug Recall Report for Releana® showed that CPCC dispensed 5958
27 prescriptions for Releana® from October 1, 2010 to March 8, 2011. Thirty patients from the
28

1 Drug Recall Report were randomly selected and their Patient Drug Histories from March 8, 2010
2 to March 8, 2011 and prescriptions for Releana® were reviewed by Board inspectors.

3 37. The Drug Histories and Releana® prescriptions for the following patients were
4 reviewed:

Patient initials	Prescriber's initials	Releana® Rx Number	Date dispensed
K.C.	D.T.	Not available ¹	Not available
G.D.	A.H.	623609	11/12/2009
E.T.	R.G.	672251	2/22/2011
M.W.	D.I.	662399	12/29/2010
M.F.	F.V.	662302	12/28/2010
D.G.	N.L.	650860	7/26/2010
A.K.	D.B.	655068	9/10/2010
H.M.	D.D.	652872	8/20/2010
G.M.	L.E.	655753	9/21/2010
B.C.	H.M.	661771	12/16/2010
P.C.	S.E.	635667	3/8/2010
Q.W.	S.B.	658717	11/1/2010
D.R.	R.W.	630300	1/26/2010
L.P.	J.B.	658030	10/21/2010
L.D.	J.W.	658261	10/26/2010
V.F.	T.P.	670762	1/31/2011
M.E.	L.K.	632162	2/9/2010
K.D.	A.T.	660151	11/18/2010
B.F.	P.M.	645830	6/1/2010

26
27 ¹ According to K.C.'s Patient Drug History, seven prescriptions for Releana® were
28 dispensed for this patient. However, a sample Releana® prescription was not provided to the Board inspectors. A prescription for testosterone was provided instead.

1	T.F.	G.J.	657118	10/11/2010
2	C.C.	G.J.	657120	10/11/2010
3	Patient initials	Prescriber's initials	Releana® Rx Number	Date dispensed
4	D.C.	U.K.	647200	6/15/2010
5	J.B.	T.L.	656880	10/8/2010
6	S.B.	M.S.	656960	10/8/2010
7	A.A.	D.P.	631816	2/8/2010
8	A.B.	H.S.	633855	2/24/2010
9	D.A.	A.D.	660830	12/2/2010
10	B.A.	E.M.	634248	2/26/2010
11	J.A.	A.D.	660833	12/2/2010
12	P.A.	R.C.	670879	2/1/2011

14 38. A review of the original prescriptions revealed that the Releana® prescriptions for
15 each patient were cut out from the prescription form sent by Millenium to CPCC and affixed to a
16 blank telephone prescription pad. A date was stamped on the prescription pads that appeared to
17 be the date the prescriptions were filled. The prescriptions contained the name and address of the
18 patient, the pre-printed drug name "human chorionic gonadotropin proprietary formula" and the
19 provider's signature. The prescriptions did not have the strength of HCG and the quantity
20 prescribed was specified in units of "1", "2" or "3." There were no notations on the prescriptions
21 indicating the pharmacist verified the prescriptions with the physicians since the prescriptions
22 were electronically received from Millenium instead of from the prescribing physicians. Many of
23 the prescribing physicians were located out of the state of California.

24 39. Affixed to the prescriptions were the prescription backer labels. The backer labels
25 indicated the prescription number assigned, the patient's name, the physician's name, the drug
26 dispensed (Releana – Chorionic Gonadotropin), the quantity, the instruction "Use as Directed by
27 Physician," and notations with CPCC's compounding lot number for the product dispensed and
28

1 the pharmacist's initials. The prescription backer label did not state the concentration, volume or
2 weight of the active ingredient nor the quantity of the drug dispensed. Prescriptions labels that
3 were duplicates of the prescription labels on the drug containers were also obtained. The
4 duplicate prescription labels did not state the concentration, volume or weight of the active
5 ingredient nor the quantity of the drug dispensed.

6 **FIRST CAUSE FOR DISCIPLINE**

7 **AGAINST CALIFORNIA PHARMACY AND COMPOUNDING CENTER**

8 **AND DAVID JOSEPH SCHAPIRO**

9 **(Violation of Pharmacy Law – Failure to Ensure Integrity of Prescription)**

10 40. Respondents CPCC and Schapiro are subject to discipline pursuant to Code section
11 4301, subdivisions (j) and (o), for violating Code section 4071 and Health and Safety Code
12 section 11164 in that Respondents failed to ensure the security, integrity and/or authority of J.S.'s
13 prescription by failing to verify the prescription with the prescribing physician, as more fully set
14 forth in paragraphs 29 – 30, which are incorporated by this reference as though set forth in full
15 herein.

16 **SECOND CAUSE FOR DISCIPLINE**

17 **AGAINST CALIFORNIA PHARMACY AND COMPOUNDING CENTER**

18 **AND DAVID JOSEPH SCHAPIRO**

19 **(Violation of Pharmacy Law - Erroneous and Uncertain Prescriptions)**

20 41. Respondents CPCC and Schapiro are subject to discipline pursuant to Code section
21 4301, subdivisions (j) and (o), for violating Code section 4040; title 16, CCR, section 1761; and,
22 Health and Safety Code section 11164. Respondents compounded and/or dispensed prescriptions
23 for Releana® containing significant errors, omissions, irregularities and/or uncertainties as more
24 fully set forth in paragraphs 29 – 38, which are incorporated by this reference as though set forth
25 in full herein, and as follows:

26 a. The prescriptions for Releana® did not specify the quantity to dispense, the directions
27 for use and the date the prescription was issued.

1 b. The electronically transmitted prescriptions for Releana® were not valid in that the
2 prescriptions were received by CPCC from Millenium instead of the prescriber and were not
3 verified with the prescribing physician by the CPCC.

4 c. The electronically transmitted prescriptions for Releana® that were produced into a
5 hard copy did not bear the date the prescription was transcribed or the signature of the
6 transcribing pharmacist.

7 d. The electronically transmitted prescriptions for Releana® did not have the name of
8 the person at the prescriber's office who transmitted the prescriptions.

9 **THIRD CAUSE FOR DISCIPLINE**

10 **AGAINST CALIFORNIA PHARMACY AND COMPOUNDING CENTER**

11 **AND DAVID JOSEPH SCHAPIRO**

12 **(Selling to Unlicensed Entity)**

13 42. Respondents CPCC and Schapiro are subject to discipline pursuant to Code section
14 4301, subdivision (o) for violation of section 4169, subdivision (a)(1), for selling dangerous drugs
15 to an entity not licensed by the Board. Respondents compounded and sold Releana® to
16 Millenium, an entity not licensed by the Board as a pharmacy or wholesaler in California, as is
17 more fully set forth in paragraphs 29 – 38, which are incorporated by this reference as though set
18 forth in full herein.

19 **FOURTH CAUSE FOR DISCIPLINE**

20 **AGAINST CALIFORNIA PHARMACY AND COMPOUNDING CENTER**

21 **AND DAVID JOSEPH SCHAPIRO**

22 **(Selling Misbranded Drugs)**

23 43. Respondents CPCC and Schapiro are subject to discipline pursuant to Code sections
24 4301, subdivisions (j) and (o) for violation of section 4169, subdivision (a)(3), and Health and
25 Safety Code sections 11130, 111440 and 11340, for selling, delivering, transferring, holding or
26 offering for sale, any drug that Respondents knew or should reasonably have known were
27 misbranded. The Releana® drugs were misbranded in that the label affixed to each individual
28 container of Releana® powder and Releana® vehicle, did not specify the name and address of the

1 manufacturer, packer or distributor and they did not specify the quantity of the contents of each of
2 the two containers sold in terms of weight or measure, as is more fully set forth in paragraphs 29-
3 38, which are incorporated by this reference as though set forth in full herein.

4 **FIFTH CAUSE FOR DISCIPLINE**

5 **AGAINST CALIFORNIA PHARMACY AND COMPOUNDING CENTER**

6 **AND DAVID JOSEPH SCHAPIRO**

7 **(Dispensing Incorrectly Labeled Prescriptions)**

8 44. Respondents CPCC and Schapiro are subject to discipline pursuant to Code section
9 4301, subdivision (o) for violation of section 4076, subdivision (a)(7) and (8) and title 16, CCR,
10 1735.4, for dispensing incorrectly labeled Releana® prescriptions in that Respondents dispensed
11 Releana® with prescription labels that did not state the concentration or strength of the active
12 ingredient nor the quantity of the drug dispensed, either in volume, weight or numerical count, as
13 is more fully set forth in paragraphs 29 - 38, which are incorporated by this reference as though
14 set forth in full herein.

15 **SIXTH CAUSE FOR DISCIPLINE**

16 **AGAINST CALIFORNIA PHARMACY AND COMPOUNDING CENTER**

17 **AND DAVID JOSEPH SCHAPIRO**

18 **(Aiding or Abetting Millenium in Sale of Controlled Substances)**

19 45. Respondents CPCC and Schapiro are subject to discipline pursuant to Code section
20 4301, subdivision (o) for assisting in or abetting the violation of Code section 4110 by Millenium,
21 in that Millenium sold Releana® to physicians in California, among other states, without having a
22 license as a pharmacy or wholesaler in the State of California, as more fully set forth in
23 paragraphs 29 - 38 and incorporated by this reference as though set forth in full herein.

24 **PRAYER**


25 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,
26 and that following the hearing, the Board of Pharmacy issue a decision:

27 1. Revoking or suspending Pharmacy Permit Number PHY 49828 issued to California
28 Pharmacy and Compounding Center;

- 1 2. Revoking or suspending Sterile Compounding License Number LSC 99542 issued to
2 California Pharmacy and Compounding Center;
3 3. Revoking or suspending Pharmacist License Number RPH 26704 issued to David
4 Joseph Schapiro;
5 4. Ordering California Pharmacy and Compounding Center to pay the Board of
6 Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to
7 Business and Professions Code section 125.3;
8 5. Ordering David Joseph Schapiro to pay the Board of Pharmacy the reasonable costs
9 of the investigation and enforcement of this case, pursuant to Business and Professions Code
10 section 125.3; and,
11 6. Taking such other and further action as deemed necessary and proper.

12
13 DATED:

3/27/14


VIRGINIA HEROLD
Executive Officer
Board of Pharmacy
Department of Consumer Affairs
State of California
Complainant

14
15
16
17 SD2013805160/70730133.doc
18
19
20
21
22
23
24
25
26
27
28